Sales up 9% at DePuy
This article was originally published in Clinica
US orthopaedics specialist DePuy reported a 14% increase in first-quarter net income, to $31 million, on sales that were up 9% to $188 million. Net income gains were attributed largely to higher global sales of joint reconstructive products and spinal implants.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.